Brief: Eloxx Pharmaceuticals Opens Clinical Trial Sites For Mid-Stage Study of Alport Syndrome Therapy
01/11/2022 21:28
Nov 1 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS ANNOUNCES OPENING OF CLINICAL TRIAL
SITES
FOR PHASE 2 STUDY OF ELX-02 FOR THE TREATMENT OF ALPORT SYNDROME
Source text for Eikon: ID:nGNX3JfG4b
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome